Sleep quality and preclinical Alzheimer disease
- PMID: 23479184
- PMCID: PMC3676720
- DOI: 10.1001/jamaneurol.2013.2334
Sleep quality and preclinical Alzheimer disease
Abstract
Importance: Sleep and circadian problems are very common in Alzheimer disease (AD). Recent animal studies suggest a bidirectional relationship between sleep and β-amyloid (Aβ), a key molecule involved in AD pathogenesis.
Objective: To test whether Aβ deposition in preclinical AD, prior to the appearance of cognitive impairment, is associated with changes in quality or quantity of sleep.
Design: Cross-sectional study conducted from October 2010 to June 2012.
Setting: General community volunteers at the Washington University Knight Alzheimer's Disease Research Center.
Participants: Cognitively normal individuals (n = 145) 45 years and older were recruited from longitudinal studies of memory and aging at the Washington University Knight Alzheimer's Disease Research Center. Valid actigraphy data were recorded in 142. The majority (124 of 142) were recruited from the Adult Children Study, in which all were aged 45 to 75 years at baseline and 50% have a parental history of late-onset AD. The rest were recruited from a community volunteer cohort in which all were older than 60 years and healthy at baseline.
Main outcome measures: Sleep was objectively measured using actigraphy for 2 weeks. Sleep efficiency, which is the percentage of time in bed spent asleep, was the primary measure of sleep quality. Total sleep time was the primary measure of sleep quantity. Cerebrospinal fluid Aβ42 levels were used to determine whether amyloid deposition was present or absent. Concurrent sleep diaries provided nap information.
Results: Amyloid deposition, as assessed by Aβ42 levels, was present in 32 participants (22.5%). This group had worse sleep quality, as measured by sleep efficiency (80.4% vs 83.7%), compared with those without amyloid deposition, after correction for age, sex, and APOEε4 allele carrier status (P = .04). In contrast, quantity of sleep was not significantly different between groups, as measured by total sleep time. Frequent napping, 3 or more days per week, was associated with amyloid deposition (31.2% vs 14.7%; P = .03).
Conclusions and relevance: Amyloid deposition in the preclinical stage of AD appears to be associated with worse sleep quality but not with changes in sleep quantity.
Figures
Comment in
-
Sleep evaluation by actigraphy for patients with Alzheimer disease.JAMA Neurol. 2013 Aug;70(8):1074. doi: 10.1001/jamaneurol.2013.3163. JAMA Neurol. 2013. PMID: 23939591 No abstract available.
-
Sleep evaluation by actigraphy for patients with Alzheimer disease--reply.JAMA Neurol. 2013 Aug;70(8):1074-5. doi: 10.1001/jamaneurol.2013.3490. JAMA Neurol. 2013. PMID: 23939592 No abstract available.
Similar articles
-
Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease.JAMA Neurol. 2018 May 1;75(5):582-590. doi: 10.1001/jamaneurol.2017.4719. JAMA Neurol. 2018. PMID: 29379963 Free PMC article.
-
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060. JAMA Psychiatry. 2014. PMID: 25162367
-
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.Lancet Neurol. 2013 Oct;12(10):957-65. doi: 10.1016/S1474-4422(13)70194-7. Epub 2013 Sep 4. Lancet Neurol. 2013. PMID: 24012374 Free PMC article.
-
The sleep-wake cycle and Alzheimer's disease: what do we know?Neurodegener Dis Manag. 2014;4(5):351-62. doi: 10.2217/nmt.14.33. Neurodegener Dis Manag. 2014. PMID: 25405649 Free PMC article. Review.
-
Neuroendocrine-Metabolic Dysfunction and Sleep Disturbances in Neurodegenerative Disorders: Focus on Alzheimer's Disease and Melatonin.Neuroendocrinology. 2019;108(4):354-364. doi: 10.1159/000494889. Epub 2018 Oct 28. Neuroendocrinology. 2019. PMID: 30368508 Review.
Cited by 177 articles
-
Slow Wave Sleep Is a Promising Intervention Target for Alzheimer's Disease.Front Neurosci. 2020 Jun 30;14:705. doi: 10.3389/fnins.2020.00705. eCollection 2020. Front Neurosci. 2020. PMID: 32714142 Free PMC article. Review.
-
Association of Modifiable Lifestyle Factors With Cortical Amyloid Burden and Cerebral Glucose Metabolism in Older Adults With Mild Cognitive Impairment.JAMA Netw Open. 2020 Jun 1;3(6):e205719. doi: 10.1001/jamanetworkopen.2020.5719. JAMA Netw Open. 2020. PMID: 32515796 Free PMC article.
-
Impaired Hippocampal-Cortical Interactions during Sleep in a Mouse Model of Alzheimer's Disease.Curr Biol. 2020 Jul 6;30(13):2588-2601.e5. doi: 10.1016/j.cub.2020.04.087. Epub 2020 May 28. Curr Biol. 2020. PMID: 32470367
-
Sleep Disturbances in MCI and AD: Neuroinflammation as a Possible Mediating Pathway.Front Aging Neurosci. 2020 May 8;12:69. doi: 10.3389/fnagi.2020.00069. eCollection 2020. Front Aging Neurosci. 2020. PMID: 32457592 Free PMC article. Review.
-
Association of sleep with cognition and beta amyloid accumulation in adults with Down syndrome.Neurobiol Aging. 2020 Sep;93:44-51. doi: 10.1016/j.neurobiolaging.2020.04.018. Epub 2020 Apr 29. Neurobiol Aging. 2020. PMID: 32447011
Publication types
MeSH terms
Substances
Grant support
- P01-AG03991/AG/NIA NIH HHS/United States
- P01-AG026276/AG/NIA NIH HHS/United States
- L30 AG043312/AG/NIA NIH HHS/United States
- P01 NS074969/NS/NINDS NIH HHS/United States
- P01 AG003991/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P01 AG026276/AG/NIA NIH HHS/United States
- UL1 RR024992/RR/NCRR NIH HHS/United States
- P01-NS074969/NS/NINDS NIH HHS/United States
- P50-AG05681/AG/NIA NIH HHS/United States
- UL1 TR000448/TR/NCATS NIH HHS/United States
- KL2 RR024994/RR/NCRR NIH HHS/United States
- KL2 TR000450/TR/NCATS NIH HHS/United States
LinkOut - more resources
-
Full Text Sources
-
Medical
-
Research Materials